{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Week 156"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Week 208"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Week 260"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Proportion of patients who achieved partial remission at Week 104, based on the ELN and IWG-MRT criteria, as defined by:\n\n* MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 104, and\n* Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8, and\n* WBC \\< 10 x10\\^9/L at Week 104, and\n* Platelets ≤ 400 x 10\\^9/L at Week 104, and\n* No palpable spleen at Week 104, and\n* No hemorrhagic or thrombotic events, and\n* No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria) Endpoint for Week 156, Week 208 and Week 260 are defined, similarly.","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure. Data after crossover for participants randomized to BAT were not collected.","reportingStatus":"POSTED","timeFrame":"From Week 8 to Week 104, 156, 208 and 260","title":"Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.","type":"SECONDARY","unitOfMeasure":"Participants"}